Glasgow's Queen Elizabeth University Hospital haematology service manages ITP patients requiring long-term thrombopoietin receptor agonist therapy. Eltromag 25mg offers the same clinical efficacy as brand Promacta and Revolade at significantly reduced cost for Scottish patients seeking private or supplementary access.
Eltromag stimulates bone marrow platelet production by activating the thrombopoietin receptor on progenitor cells. It's NICE-approved for chronic ITP patients who haven't responded adequately to corticosteroids, immunoglobulins, or splenectomy. Starting dose is 25mg daily, titrated based on platelet count response to find the minimum effective dose.
Brand Promacta/Revolade costs over £4,000 monthly in the UK private market. Eltromag from WHO-GMP certified Indian manufacturers provides identical benefit, making long-term ITP management financially viable for Glasgow patients. Visit medshopy.com or WhatsApp +91 82650 41513.
Eltromag stimulates bone marrow platelet production by activating the thrombopoietin receptor on progenitor cells. It's NICE-approved for chronic ITP patients who haven't responded adequately to corticosteroids, immunoglobulins, or splenectomy. Starting dose is 25mg daily, titrated based on platelet count response to find the minimum effective dose.
Brand Promacta/Revolade costs over £4,000 monthly in the UK private market. Eltromag from WHO-GMP certified Indian manufacturers provides identical benefit, making long-term ITP management financially viable for Glasgow patients. Visit medshopy.com or WhatsApp +91 82650 41513.